Clinical, Virologic, and Immunologic Evaluation of Symptomatic Coronavirus Disease 2019 Rebound Following Nirmatrelvir/Ritonavir Treatment is a research paper published in Clinical Infectious Diseases (2022). On theSindex it has a DataRank of 2.9. It has been cited 52 times, with 49 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.596
From this paper's citation signal
Citation Network Contribution
2.4
From 39 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 49 citers.
NCI NIH HHS
Grant: 75N91019D00024
NCI NIH HHS
Grant: HHSN261201500003I
NCI NIH HHS
Grant: HHSN261201500003C
National Cancer Institute
National Institute of Allergy and Infectious Diseases
National Institutes of Health
FWCI
4.63
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals